Loading...

ASMB ASSEMBLY BIOSCIENCES INC Other Situations 8-K Filing

SSMB

SMB

ASSEMBLY BIOSCIENCES INC

(ASMB)

2025 8-K

Show Summary

Summary

Amendments to stock plans

Financial Statements

Financial Results

Clinical Study Results

Sublease Amendment

Clinical Study Results

Collaboration Update

Stock Sale Agreement

Financial Results

Clinical Study Update

Financial Results Announcement

Equity Financing Registered...

Stock Incentive Plan and Em...

Financial Results Announcement

Financial Results Announcement

Appointment and Bonus Plan ...

Reverse Stock Split

Special Meeting Results

Termination of License Agre...

Appointment, Headquarters C...

Earnings Reports

Collaboration Agreement wit...

Financial Results Announcement

Sublease Agreement

Annual Meeting Approval

Financial Results Announcement

Clinical Study Results

Financial Results and Clini...

External Links:

On June 25, 2025, Assembly Biosciences, Inc. announced topline results from a Phase 1b trial of ABI-4334, a treatment for chronic hepatitis B virus infection. This filing reflects a development in their clinical research efforts.

AI Assistant

ASSEMBLY BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.